New Retina Radio
New Retina Radio

02.11.22

Exploring the clinical development program for an innovative, continuous delivery treatment for nAMD

Recently, the first refillable, intraocular device that enables continuous delivery of therapy was FDA approved for nAMD. John Kitchens, MD sits down with one of the investigators, Dante Pieramici, MD, to learn more about his experiences with the clinical development program and this innovative drug delivery system. This special episode of New Retina Radio is supported by Genentech USA, Inc., which is responsible for its content.

View full description +

MORE EPISODES

06.22.26

Spotlight on UNITY® VCS: Experience Extraordinary

Kourous Rezaei, MD; with Lejla Vajzovic, MD, FASRS and Aleksandra Rachitskaya, MD, FASRS

06.18.26

ARVO '26: TKIs for Wet AMD and How We Got to the AI Era of Research

Akshay Thomas, MD; Aaron Lee, MD, MSCI; and Cecelia Lee, MD, MS

06.15.26

Spotlight on UNITY® VCS Dynamic Stiffener 27+

Christina Weng, MD, MBA, FASRS; Mrinali Gupta, MD, FASRS; and Omesh Gupta, MD, MBA

06.08.26

Spotlight on UNITY® VCS: UNITY for All

Sarwar Zahid, MD, FASRS; John Kitchens, MD and Matthew Cunningham, MD, FASRS

06.04.26

ARVO '26: DME Delphi Study and RHONE-X

Baruch Kuppermann, MD, PhD; and Murtaza Adam, MD

05.15.26

New Retina Radio Journal Club w/ VBS: Observation vs. Vitrectomy for Floaters

Kyle Kovacs, MD; Matthew Starr, MD; and Nita Valikodath, MD

05.11.26

The Fellow Eye: Episode 4

David Fell, MD; Justin C. Muste, MD; Allen C. Ho, MD; and Curtis Heisel, MD, MBA

05.08.26

Extending Treatment Efficacy in Wet AMD

Lejla Vajzovic, MD; Robert L. Avery, MD; Carl D. Regillo, MD; and Durga S. Borkar, MD, MMCi

Show More